Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia.

Abstract

Recent studies of 6MP pharmacokinetics in children with ALL have suggested that a higher systemic exposure, as measured by a greater area under the plasma concentration time curve or a higher concentration of 6MP metabolites in red blood cells, is associated with a decreased risk of relapse.